Aromatase inhibitors associated osteonecrosis of jaw: signal refining to identify pseudo safety signals

Int J Clin Pharm. 2020 Apr;42(2):721-727. doi: 10.1007/s11096-020-01018-z. Epub 2020 Apr 8.

Abstract

Background Signal generation through data mining algorithms is an innovative and emerging field in pharmacovigilance. Early detection of safety signals is important for public health safety. However, the possibility of generating pseudo signals should not be overlooked. Objective Our study aimed to identify potential signals of aromatase inhibitors associated Osteonecrosis of Jaw and assess the possibilities of the safety signal to be a pseudo signal/false positive in FDA Adverse Event Reporting System (FAERS). Setting Spontaneously reported data in FAERS database. Methods Data for this study were obtained from the public release of data in FAERS. OpenVigil, a pharmacovigilance analytical tool was used to access FAERS data. Reporting Odds Ratio (ROR) was used to assess the relation between the drug and adverse event. A value of ROR-1.96SE > 1, (SE-standard error) was considered positive. Main outcome measure Signal strength. Results FAERS database had a total of 15,178 reports for Osteonecrosis of Jaw. Amongst which 617 reports were associated with aromatase inhibitors. Signal strength ROR (lower bound of the 95% CI) for letrozole, anastrozole and exemestane associated Osteonecrosis of Jaw without any background correction was 8.34, 6.64 and 15.14 respectively. Upon removing the reports of concomitantly administered drugs (bisphosphonates and denosumab), signal strength drastically decreased to 0.03, 0.36 and 0.47 for letrozole, anastrozole and exemestane respectively. The signal strength of bisphosphonates and denosumab associated Osteonecrosis of Jaw was not changed significantly upon removal of aromatase inhibitors. Conclusion Our study concluded that the signal generated for aromatase inhibitors associated Osteonecrosis of Jaw in FAERS database can be false positive. Careful background corrections with identification of those risk factors are imperative to exclude false positive results.

Keywords: Aromatase inhibitors; Confounding factors; FDA adverse event reporting system; Jaw osteonecrosis; Pseudo signals; Signal detection.

MeSH terms

  • Adverse Drug Reaction Reporting Systems
  • Aromatase Inhibitors / administration & dosage
  • Aromatase Inhibitors / adverse effects*
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / diagnosis
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / epidemiology
  • Diphosphonates / administration & dosage
  • Diphosphonates / adverse effects
  • Drug Therapy, Combination
  • False Positive Reactions
  • Humans
  • Jaw Diseases / chemically induced*
  • Jaw Diseases / diagnosis
  • Jaw Diseases / epidemiology*
  • Osteonecrosis / chemically induced*
  • Osteonecrosis / diagnosis
  • Osteonecrosis / epidemiology*
  • Pharmacovigilance
  • United States / epidemiology
  • United States Food and Drug Administration / standards*

Substances

  • Aromatase Inhibitors
  • Diphosphonates